212 related articles for article (PubMed ID: 33105486)
1. MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients.
Saini M; Jha AN; Tangri R; Qudratullah M; Ali S
Hum Mol Genet; 2021 Jan; 29(21):3532-3545. PubMed ID: 33105486
[TBL] [Abstract][Full Text] [Related]
2. High CHI3L1 expression is associated with glioma patient survival.
Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
[TBL] [Abstract][Full Text] [Related]
3. Expression level of human miR-34a correlates with glioma grade and prognosis.
Gao H; Zhao H; Xiang W
J Neurooncol; 2013 Jun; 113(2):221-8. PubMed ID: 23529798
[TBL] [Abstract][Full Text] [Related]
4. RAB34 was a progression- and prognosis-associated biomarker in gliomas.
Wang HJ; Gao Y; Chen L; Li YL; Jiang CL
Tumour Biol; 2015 Mar; 36(3):1573-8. PubMed ID: 25501506
[TBL] [Abstract][Full Text] [Related]
5. Insular glioma resection: assessment of patient morbidity, survival, and tumor progression.
Sanai N; Polley MY; Berger MS
J Neurosurg; 2010 Jan; 112(1):1-9. PubMed ID: 19612970
[TBL] [Abstract][Full Text] [Related]
6. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas.
Fan X; Wang Y; Zhang C; Liu X; Qian Z; Jiang T
J Neuroimmunol; 2016 May; 294():27-31. PubMed ID: 27138095
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
9. ZIP4 is a novel molecular marker for glioma.
Lin Y; Chen Y; Wang Y; Yang J; Zhu VF; Liu Y; Cui X; Chen L; Yan W; Jiang T; Hergenroeder GW; Fletcher SA; Levine JM; Kim DH; Tandon N; Zhu JJ; Li M
Neuro Oncol; 2013 Aug; 15(8):1008-16. PubMed ID: 23595627
[TBL] [Abstract][Full Text] [Related]
10. Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients.
Kinker GS; Thomas AM; Carvalho VJ; Lima FP; Fujita A
Sci Rep; 2016 Apr; 6():24160. PubMed ID: 27052952
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma.
Shee K; Chambers M; Hughes EG; Almiron DA; Deharvengt SJ; Green D; Lefferts JA; Andrew AS; Hickey WF; Tsongalis GJ
J Neurooncol; 2020 Jul; 148(3):473-480. PubMed ID: 32583303
[TBL] [Abstract][Full Text] [Related]
13. High level of Sema3C is associated with glioma malignancy.
Vaitkienė P; Skiriutė D; Steponaitis G; Skauminas K; Tamašauskas A; Kazlauskas A
Diagn Pathol; 2015 Jun; 10():58. PubMed ID: 26032848
[TBL] [Abstract][Full Text] [Related]
14. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
15. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma.
Guan Y; Chen L; Bao Y; Qiu B; Pang C; Cui R; Wang Y
Int J Clin Exp Pathol; 2015; 8(6):6576-88. PubMed ID: 26261539
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Tan D; Pang FM; Li D; Zhang L; Wu J; Liu ZQ; Li X; Yan H
Future Oncol; 2018 Jun; 14(13):1273-1284. PubMed ID: 29741404
[TBL] [Abstract][Full Text] [Related]
17. High expression of forkhead box protein C2 is related to poor prognosis in human gliomas.
Wang YW; Yin CL; Zhang HY; Hao J; Yang YY; Liao H; Jiao BH
Asian Pac J Cancer Prev; 2014; 15(24):10621-5. PubMed ID: 25605149
[TBL] [Abstract][Full Text] [Related]
18. Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis.
Lehman NL; Usubalieva A; Lin T; Allen SJ; Tran QT; Mobley BC; McLendon RE; Schniederjan MJ; Georgescu MM; Couce M; Dulai MS; Raisanen JM; Al Abbadi M; Palmer CA; Hattab EM; Orr BA
Acta Neuropathol Commun; 2019 Mar; 7(1):42. PubMed ID: 30876455
[TBL] [Abstract][Full Text] [Related]
19. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma.
Pang C; Guan Y; Zhao K; Chen L; Bao Y; Cui R; Li G; Wang Y
Int J Clin Exp Pathol; 2015; 8(5):4943-52. PubMed ID: 26191187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
